HTA and Reimbursement Status of Metastatic Hormone­Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.

Bencina, Goran; Petrova, Elina; Sönmez, Demet; Matos Pereira, Sonia; Dimitriadis, Ioannis; Salomonsson, Stina

HTA and Reimbursement Status of Metastatic HormoneSensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.

Bencina, Goran; Petrova, Elina; Sönmez, Demet; Matos Pereira, Sonia; Dimitriadis, Ioannis; Salomonsson, Stina.

Afiliação

Bencina G; Center for Observational and Real-World Evidence, MSD, Madrid, Spain.
Petrova E; Market Access and Pricing, MSD, Sofia, Bulgaria.
Sönmez D; Center for Observational and Real-World Evidence, MSD, Stockholm, Sweden.
Matos Pereira S; Market Access, MSD, Lisbon, Portugal.
Dimitriadis I; Medical Affairs, MSD, Athens, Greece.
Salomonsson S; Center for Observational and Real-World Evidence, MSD, Stockholm, Sweden.

J Health Econ Outcomes Res ; 10(1): 102-110, 2023.

Article em En | MEDLINE | ID: mdl-37366384

Palavras-chave

ESMO-MCBS; HTA; anticancer drugs; patient access; prostate cancer; reimbursement decision

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Health_technology_assessment / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google